Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00131001
Status:
UNKNOWN
Last Update Posted:
2008-10-20
First Post:
2005-08-16
Brief Title:
CARMEDAS Cost-Effectiveness Analysis of Imaging Strategies in Symptomatic Carotid Stenosis
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Cost-Effectiveness Analysis of Imaging Strategies in Symptomatic Carotid Stenosis
Status:
UNKNOWN
Status Verified Date:
2007-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PURPOSE The purpose of this clinical trial is to study the cost-effectiveness ratios of diagnostic strategies for the imaging assessment of symptomatic carotid stenosis
MATERIALS AND METHODS The diagnostic accuracies of Doppler ultrasound DUS contrast-enhanced magnetic resonance angiography CEMRA and computed tomography angiography CTA were compared with digital subtraction angiography DSA in a multicenter study CARMEDAS 206 patients assessable and in a meta-analysis for CEMRA and CTA The direct costs of each imaging method were calculated in 2 university medical centers Eight hypothetical models were studied with DUS considered as the first-line imaging method and either CEMRA or CTA or DSA as the second or third line method The effectiveness criterion was the number of potential avoided strokes for each strategy and for 1000 patients
MATERIALS AND METHODS The diagnostic accuracies of Doppler ultrasound DUS contrast-enhanced magnetic resonance angiography CEMRA and computed tomography angiography CTA were compared with digital subtraction angiography DSA in a multicenter study CARMEDAS 206 patients assessable and in a meta-analysis for CEMRA and CTA The direct costs of each imaging method were calculated in 2 university medical centers Eight hypothetical models were studied with DUS considered as the first-line imaging method and either CEMRA or CTA or DSA as the second or third line method The effectiveness criterion was the number of potential avoided strokes for each strategy and for 1000 patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None